Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
surufatinib + camrelizumab + nab-paclitaxel + gemcitabine
- Development stage
- Phase 3
- Lead developer
- HUTCHMED
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a four-drug combination regimen under investigation as a first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). The regimen includes: - **Surufatinib**: A small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors 1, 2, and 3 (VEGFR1–3), fibroblast growth factor receptor 1 (FGFR1), and colony-stimulating factor 1 receptor (CSF1R). It acts primarily as an antiangiogenic agent. - **Camrelizumab**: A monoclonal antibody targeting programmed cell death protein 1 (PD-1), functioning as an immune checkpoint inhibitor to enhance antitumor immune responses. - **Nab-paclitaxel**: An albumin-bound formulation of paclitaxel, which stabilizes microtubules and inhibits cell division. It is used widely in chemotherapy regimens for various cancers. - **Gemcitabine**: A nucleoside analog that inhibits DNA synthesis, commonly used in the treatment of pancreatic cancer. The combination aims to leverage antiangiogenic effects, immune checkpoint blockade, and cytotoxic chemotherapy to improve outcomes in patients with metastatic PDAC. This regimen is currently being evaluated in a multicenter Phase II/III clinical trial versus standard-of-care nab-paclitaxel plus gemcitabine[1][4][5].
- Brand names
- Abraxane (nab-paclitaxel)
02
Targets
CSF1R (Macrophage colony-stimulating factor receptor)DNA polymerase familyFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)PDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on surufatinib + camrelizumab + nab-paclitaxel + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on surufatinib + camrelizumab + nab-paclitaxel + gemcitabine.